Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib

Oncologist

Volumn 9, Issue SUPPL. 3, 2004, Pages 10-15

  Burris III, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Capecitabine; EGFR; HER 2; Letrozole; Paclitaxel; Quinazoline; Trastuzumab; Tyrosine kinase inhibitor

Indexed keywords

CAPECITABINE; DNA NUCLEOTIDYLEXOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANOREXIA; BREAST CARCINOMA; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; META ANALYSIS; NAUSEA; NICK END LABELING; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I; DRUGS, INVESTIGATIONAL; HUMANS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 2942592008     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_3-10     Document Type: Review

References (11)

1. Riese DJ 2nd, Stem DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-48.
2. Amundadottir LT, Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998;16:737-746.
3. Okano J, Gaslightwala I, Birnbaum MJ et al. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 2000;275:30934-30942.
4. Olayioye MA, Neve RM, Lane HA et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
5. Klapper LN, Kirschbaum MH, Sela M et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
6. Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895.
7. Zhou Y, Brattain M. A novel strategy of colon cancer therapy: targeting both EGFR and ErbB2 receptors. Proc Am Assoc Cancer Res 2003; 1267. Abstract 5529.
8. Rusnak DW, Affleck K, Cockerill SG et al. The characterization of novel, dual erbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-7203.
9. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-6263.
10. Burris HA, Taylor C, Jones S et al. A phase I study of GW572016 in patients with solid tumors. Proc Am Soc Clin Oncol 2003;22:258.
11. Spector N, Raefsky E, Hurwitz H et al. Safety, clinical efficacy, and biologic assessments from EGF10004: a randomized phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc Am Soc Clin Oncol 2003;22:193.